We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Complete Blood Count Parameters Associated With Pancreatic Beta-Cell Function

By LabMedica International staff writers
Posted on 19 May 2022
Print article
Image: The Sysmex XE-2100D automated hematology analyzer (Photo courtesy of Bimedis)
Image: The Sysmex XE-2100D automated hematology analyzer (Photo courtesy of Bimedis)

The pathophysiology of type 2 diabetes mellitus (T2DM) involves insulin resistance (IR) and progressive deterioration of beta-cell function (BCF). Estimation of IR and BCF is essential for screening subjects at a high risk of T2DM and making treatment plans in clinical practice.

Along with other routine tests, the complete blood count (CBC) is widely used by physicians in health checkups to determine the status of patients and healthy people. Advances in technology make it possible for automatic cell counters to measure hematologic parameters related to variations in the shape and size of cells in addition to quantitative blood cell measurements, which contribute to the diagnosis and monitoring of many diseases.

Medical Laboratorians at the Korea Association of Health Promotion (Seoul, Korea) analyzed data from health examinees that underwent health checkups at 16 health-promotion centers in 13 Korean cities during 2021. The subjects comprised 1,470 patients with normoglycemia, 1,124 with prediabetes, and 396 with diabetes.

CBC parameters including hemoglobin level, RBC indices, and white blood cell (WBC), and platelet counts were measured using the Sysmex XE-2100D analyzer (Sysmex Corporation, Kobe, Japan). Pancreatic beta-cell function (BCF) and insulin resistance (IR) were assessed using the homeostasis model assessment (HOMA)-β and HOMA-IR, respectively.

Biochemical measurements, including those of fasting serum glucose, triglycerides, high-density lipoprotein cholesterol, and creatinine were made using the Hitachi 7600 analyzer (Hitachi, Tokyo, Japan). HbA1c levels were measured using ion-exchange high-performance liquid chromatography using the HLC-723 G8 analyzer (Tosoh, Tokyo, Japan). Serum insulin was measured using an electrochemiluminescence immunoassay with the Cobas e801 (Roche Diagnostics, Mannheim, Germany).

The investigators reported that while HOMA-IR gradually increased according to red blood cell count quartiles (1.22, 1.40, 1.47, and 1.91, in the first, second, third, and fourth quartiles, respectively), there was no correlation after adjusting for waist circumference (WC) and HbA1c. The red blood cell distribution width (RDW) was associated with HOMA-β, but not with HOMA-IR. White blood cells (WBCs) were associated with HOMA-IR and HOMA-β, which was stronger in HOMA-β after adjusting for WC and HbA1c. The platelet count was correlated with HOMA-IR and HOMA-β, which only remained in HOMA-β, after adjusting for WC and HbA1c.

The authors concluded that RDW, WBC, and platelet counts were independently associated with HOMA-β in prediabetes and T2DM. This suggests that these CBC parameters could represent BCF in prediabetes and T2DM. Due to its cost-effectiveness and easy accessibility, these CBC parameters could be screened periodically in prediabetes and T2DM, along with HbA1c, to keep both physicians and patients aware of the BCF of these diseases. The study was published on May 13, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:

Korea Association of Health Promotion 
Sysmex Corporation 
Hitachi 
Tosoh 
Roche Diagnostics 

Automated ELISA-IFA-BLOT Processor AP 22
New
Gold Supplier
pHOx Analyzer
BioProfile pHOx Analyzer
New
Gold Supplier
Influenza Type A & B Test
Influenza A+B DUO
New
Microbial Infections In-Vitro Diagnostic Solution
Weezion dx

Print article

Channels

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.